Guideline concordant osimertinib and durvalumab in two US non-small cell lung cancer cohorts. This is an ASCO Meeting Abstract from the 2025 ASCO Quality Care Symposium. This abstract does not include ...
Adjusting the TMIST study design to accommodate slower than expected accrual: ECOG-ACRIN EA1151. A phase 3 study to determine the breast cancer risk reducing effect of denosumab in women carrying a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results